Treatment of rethinopathy of prematurity in infants before 27 weeks of gestation in Sweden

Hdl Handle:
http://hdl.handle.net/10147/122658
Title:
Treatment of rethinopathy of prematurity in infants before 27 weeks of gestation in Sweden
Authors:
Hartnett, C; Keeffe, MO
Publisher:
Irish Medical Jouranal
Journal:
Irish Medical Journal
Issue Date:
Feb-2011
URI:
http://hdl.handle.net/10147/122658
Item Type:
Article
Language:
en
Description:
ROP is a significant cause of blindness and an even bigger problem in the under developed world. In the developed world major advances have occurred in the diagnosis, treatment and in research. Most recent developments such as the prospective early treatment for ROP (ETROP) established the importance of proper screening and earlier treatment 1. The treatment has advanced from cryopexy to almost exclusively laser surgery 2. Research has highlighted the importance of vascular endothelial growth factor (VEGF) in determining the course of the disease which in turn has provided a new and exciting anti-VEGF treatment such as Avastin 3. The significance of these advances is that with proper screening and timing of appropriate treatment over 90% of ROP has a successful anatomical outcome. Screening is now a major issue for neonatologist and ophthalmologist. Individual guidelines exist in most countries but sometimes cause logistic and economic problems. However, advances such as use of the Retcam that can provide reproducible digital retinal image, has allowed for the possibility of screening by technicians and nurse
Keywords:
BLINDNESS; PAEDIATRICS
Local subject classification:
RETCAM; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF); RETHINOPATHY
Sponsors:
Reproduced with permission from the Irish Medical Journal

Full metadata record

DC FieldValue Language
dc.contributor.authorHartnett, Cen
dc.contributor.authorKeeffe, MOen
dc.date.accessioned2011-02-22T15:26:19Z-
dc.date.available2011-02-22T15:26:19Z-
dc.date.issued2011-02-
dc.identifier.urihttp://hdl.handle.net/10147/122658-
dc.descriptionROP is a significant cause of blindness and an even bigger problem in the under developed world. In the developed world major advances have occurred in the diagnosis, treatment and in research. Most recent developments such as the prospective early treatment for ROP (ETROP) established the importance of proper screening and earlier treatment 1. The treatment has advanced from cryopexy to almost exclusively laser surgery 2. Research has highlighted the importance of vascular endothelial growth factor (VEGF) in determining the course of the disease which in turn has provided a new and exciting anti-VEGF treatment such as Avastin 3. The significance of these advances is that with proper screening and timing of appropriate treatment over 90% of ROP has a successful anatomical outcome. Screening is now a major issue for neonatologist and ophthalmologist. Individual guidelines exist in most countries but sometimes cause logistic and economic problems. However, advances such as use of the Retcam that can provide reproducible digital retinal image, has allowed for the possibility of screening by technicians and nurseen
dc.description.sponsorshipReproduced with permission from the Irish Medical Journalen
dc.language.isoenen
dc.publisherIrish Medical Jouranalen
dc.subjectBLINDNESSen
dc.subjectPAEDIATRICSen
dc.subject.otherRETCAMen
dc.subject.otherVASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)en
dc.subject.otherRETHINOPATHYen
dc.titleTreatment of rethinopathy of prematurity in infants before 27 weeks of gestation in Swedenen
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.